Physician profile
Robert J Cleaver
NPI 1912919598
$372.05
in general payments reported to CMS, 2019-2025
12 companies · $39.99 in 2025
The $39.99 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.20 · 2020: $54.68 · 2021: $73.35 · 2022: $91.38 · 2023: $76.45 · 2025: $39.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.60 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.60 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $52.62 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $50.17 | 2022-2025 | |
| Allergan, INC. | $46.70 | 2020-2021 | |
| Coopervision INC. | $42.92 | 2020-2022 | |
| Alcon Vision LLC | $34.19 | 2023-2025 | Precision7, Total30 |
| Abbvie INC. | $33.47 | 2022-2023 | Alphagan P, Lumigan, Vuity |
| Oyster Point Pharma, INC. | $29.24 | 2023 | Tyrvaya |
| Optos, INC. | $19.41 | 2019 | |
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.24 | 2020 | |
| Aerie Pharmaceuticals, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cleaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.